Skip to main content
. 2021 Aug 10;13:6309–6317. doi: 10.2147/CMAR.S314060

Figure 2.

Figure 2

Kaplan–Meier estimates of progression-free survival with 33 patients in cohort 2, according to the different treatments: (A) Targeted drugs and chemotherapy treatment (12.6 months vs 6.3 months, P=0.001). (B) Median iPFS between targeted regimens and chemotherapy treatment (8.4 months vs 6.0 months, P=0.042).